Research Article
Clinical Presentation, Outcomes, and Treatment of Membranous Nephropathy after Transplantation
Table 1
Demographic characteristics of patients with posttransplant MN.
| | Variables | N = 41 |
| | Recipient gender – male, n(%) | 24 (58.5) | | Recipient age (years), mean ± DP | 49.4 ± 13.2 | | Pretransplant dialysis, n(%) | 40 (97.5) | | Time on dialysis (months), mean ± DP | 22.6 ± 24.1 (median = 16) | | Etiology of end-stage renal disease, n(%) | | | Membranous nephropathy | 15 (36.6) | | Lupus nephritis | 2 (4.9) | | Unknown | 9 (22) | | Chronic glomerulonephritis | 5 (12.2) | | Hypertension | 5 (12.2) | | Diabetes | 2 (4.9) | | Chronic pyelonephritis | 1 (2.4) | | Urological | 1 (2.4) | | Cortical necrosis | 1 (2.4) | | Panel reactive antibodies (%), mean ± DP | 7.85 ± 22.6 (median = 0) | | Donor source, n(%) | | | Living | 26 (63.4) | | HLA identical | 6 (14.6) | | HLA haploidentical | 16 (39) | | HLA distinct | 4 (9.8) | | Deceased | 15 (36.6) | | Standard criteria donor | 10 (24.4) | | Expanded criteria donor1 | 5 (12.2) | | Donor age (years), mean ± DP | 38.1 ± 16.3 | | HLA mismatches, mean ± DP | 2.3 ± 1.8 | | Cold ischemia time (hours), mean ± DP | 25 ± 9 | | Induction therapy, n(%) | | | None | 32 (78.1) | | Basiliximab | 1 (2.4) | | Thymoglobulin | 8 (19.5) | | Initial immunosuppressive regimen, n(%) | | | CNI-PRED-AZA | 23 (56.1) | | CNI-PRED-MPA | 14 (34.1) | | CNI PRED-SRL | 4 (9.8) |
|
|
PRED: prednisone; CNI: calcineurin inhibitor; AZA: azathioprine; MPA: mycophenolic acid; SRL: sirolimus; HLA: human leukocyte antigens. 1United Network for Organ Sharing (UNOS) criteria [ 13]. |
